<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00599495</url>
  </required_header>
  <id_info>
    <org_study_id>EBMT MUDRIC-MM</org_study_id>
    <nct_id>NCT00599495</nct_id>
  </id_info>
  <brief_title>Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT</brief_title>
  <official_title>Allogeneic Stem Cell Transplantation From Unrelated Donors After Dose-reduced Intensity Conditioning Regimen for Patients With Multiple Myeloma and Relapse After Autologous Stem Cell Transplantation: A Phase II-study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a reduced intensity conditioning regimen
      followed by allogeneic stem cell transplantation from unrelated donors is a feasible and
      effective treatment for patients with multiple myeloma who failed a previous autologous stem
      cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether a reduced intensity conditioning regimen
      followed by allogeneic stem cell transplantation from unrelated donors is a feasible and
      effective treatment for patients with multiple myeloma who failed a previous autologous stem
      cell transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment, chimerism, toxicity, non-relapse mortality</measure>
    <time_frame>Follow-up until day +1095</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of response/GvHD/ infectious complications/ disease-free survival, Prognostic impact of cytogenetic, Evaluation of incidence and prognostic impact of molecular remission in patients with clinically complete remission.</measure>
    <time_frame>Follow-up until day +1095</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic HSCT</intervention_name>
    <description>dose-reduced conditioning regimen</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Multiple Myeloma stage II or III acc. to Salmon and Durie (chemosensitive or
             refractory) and relapse or progression after high dose chemotherapy with autologous
             stem cell support

          -  Age 18-60 years

          -  ECOG-performance status 0-1

          -  Availability of a HLA-compatible unrelated donor (HLA-A, -B, -DRB1, -DQB1)

        Exclusion Criteria:

          -  Serious concomitant medical disease that would limit life span or ability to tolerate
             chemotherapy

          -  Severe cardiac failure (ejection fraction &lt; 40%)

          -  Severe impairment of renal function (Creatinine clearance &lt; 50ml/min)

          -  Severe impairment of liver function (bilirubine &gt; 2 fold of upper limits of normal)

          -  Pregnant or lactating women

          -  Other major organ or system dysfunctions(GI, neurological, psychiatric dysfunctions
             that would impair tolerance of chemotherapy or prolonged haematological recovery)

          -  Positivity for HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolaus Kroeger, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2008</study_first_submitted>
  <study_first_submitted_qc>January 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2008</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

